ATP6AP2 and metabolic dysfunction-associated steatotic liver disease: The fact that PRR antagonism was unable to alter body weight, fasting blood glucose, or glucose handling in HFD-fed mice may suggest that our intervention only targets enzymatic pathways directly involved in lipid synthesis while leaving other clinical aspects of NAFLD pathology unchanged.